Theragen Etex테라젠이텍스
066700 · KOSDAQ · ₩066700 · 테라젠이텍스
₩2,020▼ ₩5 (0.25%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩272B | ₩250B | ₩222B | ₩193B | ₩167B |
| Cost of sales | ₩131B | ₩124B | ₩119B | ₩114B | ₩105B |
| Gross profit | ₩141B | ₩126B | ₩103B | ₩79B | ₩61B |
| Operating income | ₩10B | ₩12B | ₩12B | ₩10B | −₩7.4B |
| Net income | ₩12B | −₩39B | ₩28B | ₩11B | −₩11B |
| Net income to shareholders | ₩11B | −₩41B | ₩28B | ₩9.6B | −₩12B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩258B | ₩237B | ₩243B | ₩247B | ₩350B |
| Current assets | ₩174B | ₩151B | ₩115B | ₩107B | ₩97B |
| Cash and equivalents | ₩35B | ₩22B | ₩22B | ₩18B | ₩12B |
| Total liabilities | ₩98B | ₩106B | ₩90B | ₩89B | ₩116B |
| Current liabilities | ₩89B | ₩100B | ₩86B | ₩75B | ₩75B |
| Borrowings | ₩41B | ₩49B | ₩35B | ₩29B | ₩35B |
| Total equity | ₩159B | ₩131B | ₩153B | ₩158B | ₩234B |
| Shareholders' equity | ₩139B | ₩112B | ₩136B | ₩144B | ₩223B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩11B | ₩1.8B | ₩12B | ₩9.6B | ₩4B |
| Capital spending | ₩2.6B | ₩11B | ₩4.8B | ₩4.2B | ₩2.7B |
| Free cash flow | ₩8.4B | −₩9.6B | ₩7.3B | ₩5.4B | ₩1.3B |
| Dividends paid | ₩99M | ₩99M | — | — | — |
Consolidated where available. Amounts in won.
Also known as: Theragen Etex / 테라젠이텍스 / 066700 / KRX:066700
Source: KRX statistical information